On September 15, 2015, Michael Dinerman, M.D., the Chief Operating Officer and Secretary of Viking Therapeutics, Inc. to resign from his positions with the company, effective as of September 30, 2015, to pursue other opportunities.
Market Closed -
Other stock markets
|
Pre-market 07:32:14 am | |||
67.52 USD | +0.77% | 67.79 | +0.41% |
May. 17 | Raymond James Upgrades Viking Therapeutics to Strong Buy From Outperform | MT |
May. 17 | North American Morning Briefing : The "Everything -2- | DJ |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+262.79% | 7.44B | |
+9.58% | 115B | |
+12.41% | 107B | |
-3.52% | 21.6B | |
-12.38% | 22.31B | |
-6.87% | 19.19B | |
-3.35% | 18.23B | |
-38.57% | 17.62B | |
+7.51% | 14.26B | |
+35.67% | 12.37B |
- Stock Market
- Equities
- VKTX Stock
- News Viking Therapeutics, Inc.
- Viking Therapeutics, Inc. Announces Resignation of Michael Dinerman as Chief Operating Officer and Secretary